Technical Analysis for RCUS - Arcus Biosciences, Inc.

Grade Last Price % Change Price Change
C 16.41 0.37% 0.06
RCUS closed up 0.37 percent on Monday, June 24, 2024, on 76 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
200 DMA Resistance Bearish 0.37%
Pocket Pivot Bullish Swing Setup 0.37%
Volume Surge Other 0.37%
Bollinger Band Squeeze Range Contraction 0.37%
Gapped Up Strength 0.37%
Crossed Above 20 DMA Bullish 1.36%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 14 hours ago
Possible Inside Day about 14 hours ago
10 DMA Support about 14 hours ago
Down 1% about 15 hours ago
Fell Below 10 DMA about 15 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcus Biosciences, Inc. Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1

Is RCUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 25.47
52 Week Low 12.96
Average Volume 716,789
200-Day Moving Average 16.78
50-Day Moving Average 15.97
20-Day Moving Average 15.96
10-Day Moving Average 16.27
Average True Range 0.87
RSI (14) 52.38
ADX 16.6
+DI 22.75
-DI 17.42
Chandelier Exit (Long, 3 ATRs) 14.96
Chandelier Exit (Short, 3 ATRs) 17.29
Upper Bollinger Bands 17.02
Lower Bollinger Band 14.89
Percent B (%b) 0.71
BandWidth 13.33
MACD Line 0.05
MACD Signal Line -0.01
MACD Histogram 0.0539
Fundamentals Value
Market Cap 1.48 Billion
Num Shares 90.1 Million
EPS -4.00
Price-to-Earnings (P/E) Ratio -4.10
Price-to-Sales 11.87
Price-to-Book 2.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.33
Resistance 3 (R3) 17.35 17.06 17.17
Resistance 2 (R2) 17.06 16.83 17.05 17.12
Resistance 1 (R1) 16.74 16.69 16.60 16.72 17.07
Pivot Point 16.45 16.45 16.38 16.44 16.45
Support 1 (S1) 16.13 16.22 15.99 16.11 15.75
Support 2 (S2) 15.84 16.08 15.83 15.70
Support 3 (S3) 15.52 15.84 15.65
Support 4 (S4) 15.50